Idogen AB (publ) today announces that the financial calendar communicated in the Q3 report has changed.

The following changes in the calendar have been decided.

Year-end report from 8 February to 24 February.

Interim report Q1 from 9 May to 31 May

No other reporting dates have been changed.

The annual general meeting is moved from 9 May to 8 June.

For further information, please contact:

Christina Herder, Acting CEO, Idogen AB

Tel: +46 70 374 71 56

E-mail: christina.herder@idogen.com

Certified Advisor:
Vator Securities AB

The information was submitted for publication through the agency of the contact persons set out above on January 24, 2023 at 08:16 CET.

Idogen (Nasdaq First North Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. The company’s most advanced program, IDO 8 – now in clinical phase – is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies.  For these hemophiliac patients, there is significant medical need for restoring the clinical effects of their treatment with factor VIII. This is a unique market positioning that over the long term could replace immune tolerance induction (ITI) treatments, with significant market potential. The planned IDO 8 clinical trial will validate the company’s technology platform and facilitate a range of other applications in fields such as organ transplants (IDO T) and autoimmune diseases (IDO AID). More information about Idogen is available via https://www.idogen.com